UroGen Pharma Ltd.
Pitch Summary: UroGen Pharma is positioned to capitalize on its proprietary RTGel technology with its newly approved drug Zusduri, targeting a large market for non-muscle invasive bladder cancer. The company has a proven track record with its previous drug Jelmyto, and analysts project significant revenue growth, supporting a strong buy recommendation. BSD Analysis: UroGen’s RTGel […]
